about
Indications for antiviral therapy for chronic hepatitis B in pregnant mothers.Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes.Rates of liver retransplantation in the United States are declining in the era of direct-acting antiviral agents.Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome.Equitable Access to All-Oral Direct-Acting Antiviral Therapy is a Mandatory Step to Achieve Global Hepatitis C Virus Eradication.Inverse association of marijuana use with nonalcoholic fatty liver disease among adults in the United States.Nutritional Needs and Support for Children with Chronic Liver Disease.Optimizing the Nutritional Support of Adult Patients in the Setting of Cirrhosis.An Overview of Dietary Interventions and Strategies to Optimize the Management of Non-Alcoholic Fatty Liver Disease.Optimal timing for hepatitis C antiviral therapy in the peritransplant period?Hepatitis C in Pregnancy.Serum testosterone and non-alcoholic fatty liver disease in men and women in the US.Case Report of Isoniazid-Related Acute Liver Failure Requiring Liver Transplantation.The Role of Cannabinoids in the Setting of Cirrhosis.Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease.Anti-Diabetic Medications for the Pharmacologic Management of NAFLDWhen to Initiate Weight Loss Medications in the NAFLD PopulationThe Role of Vitamin E in the Treatment of NAFLDPredictors of Nonalcoholic Steatohepatitis and Significant Fibrosis in Non-Obese Nonalcoholic Fatty Liver DiseaseAssociation of Pre-Transplant Renal Function with Liver Graft and Patient Survival after Liver Transplantation in Patients with Nonalcoholic SteatohepatitisEmerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLDPotential Therapeutic Benefits of Herbs and Supplements in Patients with NAFLDAssociation between cagA negative Helicobacter pylori status and nonalcoholic fatty liver disease among adults in the United StatesExpanding Donor Pool for Liver Transplantation by Utilizing Hepatitis C Virus-Infected Donors for Uninfected RecipientsDisparities in mortality for chronic liver disease among Asian subpopulations in the United States from 2007 to 2016Changing Trends in Etiology- and Ethnicity-Based Annual Mortality Rates of Cirrhosis and Hepatocellular Carcinoma in the United StatesUnderutilization of Hepatitis C Virus Seropositive Donor Kidneys in the United States in the Current Opioid Epidemic and Direct-Acting Antiviral EraThe Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver DiseaseThe Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLDLeucocyte telomere shortening is associated with nonalcoholic fatty liver disease-related advanced fibrosisInadequate Physical Activity and Sedentary Behavior Are Independent Predictors of Nonalcoholic Fatty Liver DiseaseImpact of Nonmalignant Portal Vein Thrombosis in Transplant Recipients With Nonalcoholic SteatohepatitisPosttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity ParadoxJudicious Use of Lipid Lowering Agents in the Management of NAFLDTrends in hospitalizations for chronic liver disease-related liver failure in the United States, 2005-2014Treatment of inoperable hepatocellular carcinoma with immunotherapyDiet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortalityElevated urinary bisphenol A levels are associated with non-alcoholic fatty liver disease among adults in the United StatesExtrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
P50
Q39182583-0417B790-9384-4873-AFA4-4A75C652B6D5Q40108169-4DED4537-F956-4343-8FC3-619E7FB472C7Q40132070-387E3FCB-097D-48B3-A845-B1261F1129AFQ40450401-1B016EA8-2888-40D7-BF13-5521BDDC8C18Q45326684-1C4FDEAD-8C96-487B-8A2F-1AC58F28D1C5Q46480886-2B15A8D6-A4A2-459D-B69C-B9FED60E87D7Q47098987-DECB0428-E88E-4CB1-9870-272D800B0555Q47168832-5D4FB9F2-2806-4229-93A0-E505A922443CQ47609771-32AC09A9-9AAE-454D-B580-164374C1EF44Q47753414-80F87A87-7E78-4407-A01E-C790FB023DD7Q54226744-15FA93EA-D936-4B28-AC20-AF4A3C677B52Q54259862-B647DFF7-46E0-4EA9-B707-01CCA18A5486Q55404991-83D620AF-AD0C-45BC-898F-F2FA9DEC1FF7Q55415931-72F1ABEB-52AA-4605-82C1-AEEA1862F30DQ55452630-D66ADE4D-E1EC-48F3-9658-F137B79BC22FQ57035990-0A65682B-5AB9-4CC0-81A8-551A1CFB3C4FQ57063805-8AFD3D1D-6AFF-4796-99F1-4B8FB2D69C8FQ57151406-78E5FEAE-892E-4E7D-9D41-311D94C376F2Q57295182-34FA53F7-7672-476F-BD14-7843F4BACC16Q58109175-6232F863-C431-4C91-80C5-8D4C8981AF2FQ58716313-7DEFBE6B-2C32-4237-AE78-A5C28917314DQ58753073-1EE652C0-5262-4FA0-B3AA-055D2A1EDD38Q58778691-BA6FA7D5-9309-4762-B35B-9C52979D9A09Q59349326-1D6428FA-2250-46F9-A23E-22F772C2AEE8Q59354455-8582CF1C-EE56-40B8-A186-48D0703D4DECQ59356772-F021C90A-BAE9-451F-89AB-44F1630A3DFCQ59357171-4BC4D19C-DFFF-40EA-9016-EC27543EA288Q64081318-151C7516-A18D-4F41-B99B-F59CEC6E87A8Q64104402-33438EA9-54EF-4B59-B99C-B54DF5B602CAQ88803335-3F652700-6096-4E4C-8C2E-F4BBED6D34A3Q89506377-C90E5BFA-70BD-45EE-828A-8A99FD45B55BQ90848948-BB478E8E-28AB-4000-B2A0-B9C7EE6E8834Q91007276-C7A2C652-FEA1-44BA-82F7-03847F12CB79Q91702655-8F113EB6-56DD-4055-940C-9D2F561F7D94Q91973097-FCCA853C-5904-4FCC-81AA-92AF8B0184DAQ92226034-0F24C5FE-A085-4A36-888F-F534D75089DAQ92472644-09C72271-408B-43C9-961B-F95B048B6517Q92695797-27B49A1F-8ADC-4652-B4C3-AA087DE7FCF2Q92722364-C4825191-9D89-4059-925D-62592435852E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Aijaz Ahmed
@ast
Aijaz Ahmed
@en
Aijaz Ahmed
@es
Aijaz Ahmed
@fr
Aijaz Ahmed
@nl
Aijaz Ahmed
@sl
type
label
Aijaz Ahmed
@ast
Aijaz Ahmed
@en
Aijaz Ahmed
@es
Aijaz Ahmed
@fr
Aijaz Ahmed
@nl
Aijaz Ahmed
@sl
prefLabel
Aijaz Ahmed
@ast
Aijaz Ahmed
@en
Aijaz Ahmed
@es
Aijaz Ahmed
@fr
Aijaz Ahmed
@nl
Aijaz Ahmed
@sl
P106
P31
P496
0000-0002-3609-8586